-
Mashup Score: 1
July 14, 2023 — Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Transcatheter Closure of Perimembranous Ventricular Septal Defect Using a Novel Fully Bioabsorbable Occluder: Multicenter Randomized Controlled Trial - 9 month(s) ago
July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the closure of perimembranous ventricular septal defect (VSD). The advancements in trancatheter VSD closure have significantly contributed to its widespread adoption. Traditionally, VSD occluders are often made of shape memory alloys, such as nitinol. Although nitinol-based occluders…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor In conclusion, this novel fully #bioabsorbable #occluder with a #hybrid structure utilizing #PDO and #PLLA demonstrates the non-inferior successful and safe implantation in patients with #VSD: https://t.co/y6lXndX4zD
-
-
Mashup Score: 0BIOPACT RCT Subgroup Analyses Show Consistently Great Results for Passeo-18 Lux Drug-Coated Balloon - 9 month(s) ago
July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized controlled trial (RCT), which were presented by principal investigator Dr. Koen Deloose at LINC, the Leipzig Interventional Course 2023. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) catheter…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @BIOTRONIK_US No statistical difference observed across sub-analyses for #diabetes, #lesion length, calcium, bailout #stenting and #occlusions in head-to-head study comparing #Passeo18Lux #DCB to #InPactAdmiral DCB: https://t.co/jBGGNMldlB
-
-
Mashup Score: 0
July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology versus the Resolute Onyx Drug-Eluting Stent (DES). DynamX Bioadaptor…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @ElixirMed Elixir Medical announced enrollment completion in #INFINITY_SWEDEHEART, a prospective, multicenter, single-blind, randomized #clinicaltrial of the #DynamX #Coronary #Bioadaptor System: https://t.co/4nke98IREX
-
-
Mashup Score: 0Mount Sinai Queens Opens New Cardiac Catheterization Lab to Expedite Care for Heart Attack Patients - 10 month(s) ago
July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid and comprehensive care to hundreds of heart patients every year for life-threatening emergencies and scheduled cardiac procedures. The first cardiac catheterization lab in Astoria, it will transform treatment for patients in the growing communities of western Queens by vastly…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @MountSinaiNYC Mount Sinai Queens announced the opening of a new #cardiac #catheterization lab that will provide rapid and comprehensive care to hundreds of #heart patients: https://t.co/roaYkrIi3c
-
-
Mashup Score: 0Late-Breaking Study Data: BIOTRONIK’s Orsiro DES Outperforms Other Ultrathin Strut Drug-Eluting Stent - 10 month(s) ago
July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study investigators, Dr. Hyo-Soo Kim presented the results of a stent level analysis comparing two ultrathin strut drug-eluting stents (DES): Orsiro and Coroflex ISAR. The post-hoc comparison revealed significant differences in efficacy. HOST-IDEA is a large scale, multicenter, all-comers…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @BIOTRONIK_US A subgroup analysis of the #HOST_IDEA randomized controlled trial showed efficacy differences of #Ultrathin #Strut #DES: https://t.co/V7hsXypaKl
-
-
Mashup Score: 0CPR Therapeutics Inc. Receives Three Patents In One Week For Innovations In Cardiopulmonary Resuscitation Technology - 10 month(s) ago
July 12, 2023 — CPR Therapeutics Inc. (CPR-T), a Vermont-based medical device start-up company, announced today that it has received three U.S. patents for inventions that will contribute to the development of their breakthrough technology for cardiopulmonary resuscitation. The first patent (US11,684,542) is for CPR devices that use more than one type of compression pattern to increase blood flow…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor #CPRTherapeutics Inc. announced that it has received three U.S. #patents for #inventions that will contribute to the development of their #breakthrough #technology for #cardiopulmonary #resuscitation: https://t.co/TlZub69umv
-
-
Mashup Score: 0Discovering the Paradox of Duality at AIMed 2023 - 10 month(s) ago
The 2023 AIMed Global Summit focused on artificial intelligence (AI) in healthcare, and offered valuable insights into the latest use cases, perspectives and novel approaches in healthcare AI. The event took place June 4-7 at the San Diego Convention Center in San Diego, Calif. Throughout the summit, attendees had the opportunity to network with 1,500 healthcare game-changers and hear from top AI…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @AIMedHQ @AnthonyChangMD To move forward in #ArtificialInteligence, it is critical for the medical community to learn to look at solutions in multiple ways to develop a deeper sense of #duality: https://t.co/9L069jeYY3 #aimed23
-
-
Mashup Score: 0Advances in Artificial Intelligence: Experts Share Their Views - 10 month(s) ago
During the AIMed 2023 Summit, a panel of experts shared their personal perspective on what’s happening in artificial intelligence (AI), particularly with ChatGPT, and where they think these advances are going, in a panel discussion titled AI Foundations: 2023 Update of AI in Healthcare. The panel included Alfonso Limon, PhD, principal consultant/healthcare and AI, at Oneirix Labs; Karen B….
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @AIMedHQ @AnthonyChangMD During the #aimed23 Summit, a panel of experts shared their personal perspective on what’s happening in #ArtificialInteligence (AI), particularly with #ChatGPT: https://t.co/hoqc9jOYju
-
-
Mashup Score: 0First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study - 10 month(s) ago
July 11, 2023 — FIRE1 announced that the first U.S. patients have been successfully implanted with its FIRE1 System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where Kunjan Bhatt, MD, leads the study as Principal Investigator…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study https://t.co/Oavx63S65M
-
@DAICeditor @EliLillyandCo @VersanisBio1 A definitive agreement was reached for Lilly to acquire Versanis, a private clinical-stage #biopharmaceutical company focused on the #development of new #medicines for the treatment of #cardiometabolic #diseases: https://t.co/GFLoVTAG3B